HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
Stocks · News reference
Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39
Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Outperform rating and announces Price Target of $39.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — SpyGlass Pharma, Inc. (SGP)
Filed: 2026-10-01 AccNo: 0001778922-26-000049 Size: 219 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash
This Aehr Test Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday (CORRECTED)
Wall Street analysts changed ratings for top names. Visit our analyst ratings page for details. SGP initiated with Outperform, $39 PT.